Newsroom | 82879 results

COLTON, Calif.--(BUSINESS WIRE)--California University of Science and Medicine (CUSM) today announced that the 2025 MD graduating class received residency placements as part of the national Match Day event. Sixty-six percent of CUSM Doctor of Medicine (MD) grads will perform their residency in southern California; twenty-eight percent will remain in the Inland Empire. Match Day is the culmination of the National Resident Matching Program, in which all graduating MDs seek residency positions in...

MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 147,500 shares of common stock. Awards were made to seven new employees of the Company. The awards were granted as an inducement material to the new employees becoming employees of the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and have been approved by the Company’s Compensation Commit...

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of 29,763 restricted stock units (RSUs) of the company’s common stock to 14 newly hired non-executive employees of the company. The awards were approved by the compensation committee of the company’s board of directors under the Evolus’ 2023 Inducement Incentive Plan, with a grant and vesting commencement d...

FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified therapeutics company, today announced year end December 31, 2024 financial results, highlighted key developments in its clinical program expansion and discussed progress made across the company’s operations. “The important strategic events of the past several months have been nothing short of transformative,” stated Tivic Health Chief Executive Officer, Jennifer Ernst. “We have successfully reshaped the...

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today reported that clinical trial site activation for enrollment is underway for the company’s Phase 3 program evaluating zaltenibart in paroxysmal nocturnal hemoglobinuria (PNH). Zaltenibart (OMS906) is Omeros’ investigational inhibitor of MASP-3, the key and most proximal activator of the alternative pathway of complement. Zaltenibart inhibits the intravascular hemolysis treated by C5 inhibitors as well as the extravascular hemolysi...

DUBLIN--(BUSINESS WIRE)--The "FDA Inspection" training has been added to ResearchAndMarkets.com's offering. This seminar provides the fundamentals and the ground rules on how to prepare for and survive an FDA inspection no matter if you are a Class I, II, III device or a pharmaceutical or biologics manufacturer. This presentation will review and emphasize the do's and don'ts and cardinal rules as to interviewing, how to respond, reviewing documentation, etiquette, use of certain words, body lan...

NEW YORK--(BUSINESS WIRE)--OS Therapies (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced that Paul Romness, CEO, and Gerald Commissiong, CBO will be accepting meetings with registered investors at The Jones Healthcare and Technology Innovation Conference. The conference is being held on April 8-9, 2025 at the Venetian Resort in Las Vegas. The Company’s participation aligns with its prior...

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies, including gene elimination, gene insertion, and gene excision programs, today announced that it will publish financial results for the fourth quarter and fiscal year 2024 and provide a business update on March 26, 2025. About Precision BioSciences, Inc. Precision BioSciences, Inc. is a clinical...

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Today, Johnson & Johnson (NYSE: JNJ) (the “Company”), healthcare’s leading, most comprehensive innovation powerhouse, announced manufacturing, research and development, and technology investments of more than $55 billion in the United States over the next four years. This represents a 25% increase in investment compared to the previous four years and builds upon the Company’s already elevated U.S. investment levels resulting from the passage of the 2017...

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Enigma Biomedical USA, Inc. (EB USA) today announced that it has selected two (2) four-repeat tau (4R Tau) protein PET imaging biomarkers to advance into Phase 1 (Ph1) studies. Previously, EB USA executed an Exclusive License and Option Agreement (License) with AbbVie for the development and potential commercialization of AbbVie’s next-generation F18 PET imaging biomarkers to assess the presence of 4R Tau in subjects with suspected neurodegenerative disease. T...